Hypolipidemic treatment in patients with metabolic syndrome and chronic renal disease.

Abstract

Dyslipidemia, often present in patients with metabolic syndrome and chronic kidney disease, contributes to increased cardiovascular risk and progression of renal impairment.

Keywords

• Dyslipidemia
• metabolic syndrome
• chronic kidney disease
• statin
• fibrate
• KOLCHRI study